Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

α-1 Antitrypsin Deficiency and COPD: Screening, Classification, and Management, Slides of Pneumology

Information on the screening, classification, and management of α-1 antitrypsin deficiency and copd. It covers the risk factors, symptoms, and diagnostic tests for α-1 antitrypsin deficiency. The document also outlines the stages and characteristics of copd, as well as strategies for reducing risk factors, quitting smoking, and managing symptoms using various pharmacologic and non-pharmacologic interventions.

Typology: Slides

2011/2012

Uploaded on 12/22/2012

anna.joe
anna.joe 🇮🇳

4.6

(10)

139 documents

1 / 30

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
1
Management of Stable COPD
Definition
GOLD
Airflow limitation
{not fully reversible
{progressive
{abnormal inflammatory response to
noxious particles or gases
Docsity.com
pf3
pf4
pf5
pf8
pf9
pfa
pfd
pfe
pff
pf12
pf13
pf14
pf15
pf16
pf17
pf18
pf19
pf1a
pf1b
pf1c
pf1d
pf1e

Partial preview of the text

Download α-1 Antitrypsin Deficiency and COPD: Screening, Classification, and Management and more Slides Pneumology in PDF only on Docsity!

Management of Stable COPD

Definition

GOLD

Airflow limitation

{ not fully reversible

{ progressive

{ abnormal inflammatory response to

noxious particles or gases

2

Definition contd..

ATS

Airflow limitation due to chronic bronchitis or

emphysema

Œ generally progressive

Œ airway hyperreactivity

Œ partially reversible

Airflow Limitation Reversibility

in FEV1 > 12 > 10 > 12

in FEV1 > 200ml > 200ml

ATS ERS GOLD

4

Diagnosis

{ Symptoms + spirometry

{ Management of COPD largely symptom driven

{ Only an imperfect relationship between the

degree of airflow limitation and symptoms

Measurement of Airflow Limitation

Spirometry

{ Gold standard for diagnosis and assessment of COPD

{ Postbronchodilator FEV1 < 80% of predicted value + FEV1/FVC < 70% - confirms airflow limitation that is not fully reversible

{ FEV1/FVC more sensitive FEV1/FVC < 70% - early sign of airflow limitation when FEV1 remains normal (≥ 80% predicted)

5

Measurement of Airflow Limitation

If spirometry unavailable

o PEF good substitute if spirometry not available In COPD PEF may underestimate degree of airways obstruction

o Prolongation of FET > 6 sec → crude guide to FEV1/FVC ratio < 50%

o 6 minute walking test performed by measuring distance covered in 6 minutes when patient walks at his/her own speed (under physician supervision) o can be performed at the primary care level

Bronchodilator reversibility testing

{ To help rule out a diagnosis of asthma

{ To establish a patient’s best attainable lung

function

{ To gauge a patient’s prognosis.

Post BDR FEV1 → more reliable prognostic marker

than pre-BDR FEV

IPPB study→ degree of bronchodilator response

inversely related to rate of FEV

decline in COPD patients

7

Measurement of Airflow Limitation

{ Ratio of inspiratory to total lung capacity - an independent risk factor for mortality in patients with COPD *

{ This ratio may be a better assessment tool than FEV

{ Inspiratory capacity and lung volumes may better reflect the functional response and the improvement of symptoms and exercise tolerance induced by bronchodilator agents

  • Am J Respir Crit Care Med 2005;171:591–

BODE index

{ BODE index (Body mass index, airflow Obstruction,

Dyspnea, and Exercise capacity) - a stronger predictor than FEV1 of the risk of hospitalization and death among patients with COPD '

{ Might provide useful prognostic information

' N Engl J Med 2004;350:1005– ' Chest 2005;128:3810–

8

Exercise testing

o Functional exercise capacity - the strongest correlate of physical activity in daily life

o Recommended for more comprehensive evaluation of severity and response to treatment

o Endurance shuttle test - sensitive test for detecting changes in exercise capacity induced by bronchodilators ' and rehabilitation

' Am J Respir Crit Care Med 2005;172:1517–

ABG

{ FEV1 < 40% predicted

{ Clinical signs of respiratory failure

{ Right heart failure

10

Classification of Severity

Stage

0: At Risk

I: Mild COPD

II: Moderate COPD

III: Severe COPD

IV: Very Severe

Characteristics

. normal spirometry . chronic symptoms (cough, sputum production) . FEV1/FVC < 70% . FEV1 ≥80% predicted ± chronic symptoms (cough, sputum production) . FEV1/FVC < 70%. 50% ≤FEV1 < 80% predicted . ± chronic symptoms (cough, sputum production) . FEV1/FVC < 70% . 30% ≤FEV1 < 50% predicted . ± chronic symptoms (cough, sputum production) . FEV1/FVC < 70% . FEV1 < 30% predicted or FEV1 < 50% predicted + chronic respiratory failure

Ongoing monitoring and assessment

{ Monitor disease progression and development of complications (JVP,pitting ankle edema s/o RVF), symptoms of hypercapnia (bounding pulse, warm extremities, flaps and tremulousness) & hypoxia (tremors, restlessness, mental obtundation and cyanosis)

Spirometry - if increase in symptoms or a complication

{ Monitor pharmacotherapy and other medical Rx

{ Monitor exacerbation sputum volume / dyspnea / purulent sputum

{ Monitor Comorbidities LVF, Ca bronchus, PTB, sleep apnea,

11

Reduce risk factors

{ Quit Smoking

{ Elimination or reduction of exposures to

various substances in the workplace

{ ↓ exposure to indoor / outdoor pollution

General measures

{ (1) avoiding open burning of crop residue

(2) use of water to suppress dust (3) wearing masks at work place in areas of dust generation

{ use of smokeless ‘chullahs’

{ Substitution of solid fuels with LPG or electricity is the best approach

Pharmacotherapy for smoking

cessation

Quit rates { Placebo 6% { NRT and behavioural therapy 9% { Bupropion (6-9 wks) 18% at 1 yr

Treatment Options

Pharmacologic therapy

o Bronchodilators

o Glucocorticosteroids

o Vaccines

o Alpha-1 antitrypsin

augmentation therapy

o Antibiotics

o Mucolytics

o Antioxidants

o Immunoregulators

o Antitussives

o Vasodilators

o Respiratory Stimulants

o Narcotics

o Others

Non-pharmacologic

o Pulmonary

rehabilitation

o Oxygen

o Ventilatory support

o Surgery

Bullectomy Lung Volume Reduction Surgery (LVRS) Lung Transplantation

14

General principles

{ None of the existing medications shown to modify long-term decline in lung function { Smoking cessation and continuous long-term oxygen treatment only pharmacologic interventions that modify natural history of COPD

{ Stepwise increase in treatment

{ Treatment response variable

Bronchodilators

{ Bronchodilator medications are central to symptom management in COPD

{ Inhaled therapy preferred

{ Choice between ß2-agonist, anticholinergic, theophylline, or combination therapy depends on availability and individual response in terms of symptom relief and side effects

{ Bronchodilators prescribed on an as-needed or on a regular basis to prevent or reduce symptoms

16

ß2-agonists

Relax airway smooth muscle by stimulating ß2- adrenergic receptors, which c-AMP Oral therapy slower in onset & more side effects o Resting sinus tachycardia o Tremor o Hypokalemia o O 2 consumption show tachyphylaxis

IV: Very Severe

III: Severe

II: Moderate

0: At I: Mild Risk

New (2003)

Therapy at Each Stage of COPD

Avoidance of risk factor(s); influenza vaccination Add short-acting bronchodilator when needed

Add regular treatment with one or more long-acting bronchodilators Add rehabilitation Add i nhaled glucocorticosteroids if repeated exacerbations Add l ong-term oxygen if chronic respiratory failure Consider surgical treatments

17

ß2-agonists

Salmeterol 25-50 (MDI & DPI) 12+

Formoterol 4.5–12 (MDI & DPI) 12+

Long-acting

Terbutaline 400, 500 (DPI) 4-

Salbutamol 100, 200 (MDI & DPI) 4-

Fenoterol 100-200 (MDI) 4-

Short-acting

Duration of Drug Inhaler(ug) Action (hrs)

Anticholinergics

Salbutamol/Ipratropium 75/15 (MDI) 6-

Fenoterol/Ipratropium 200/80 (MDI) 6-

Combination

Tiotropium 18 (DPI) +

Long-acting

Oxitropium bromide 100 (MDI) 7-

Ipratropium bromide 20, 40 (MDI) 6-

Short-acting

Anticholinergics

Duration of Drug Inhaler (ug) Action (hrs)

4, 8, 16 mg Methyl-prednisolone 10-2000 mg (Pill)

5-60 mg Prednisone (Pill)

Systemic glucoco rticosteroids

25/50, 125, 250 (MDI)

Salmeterol/Fluticasone 50/100, 250, 500 (DPI)

(9/320) (DPI)

Formoterol/Budesonide 4.5/80, 160 (DPI)

Combination

Triamcinolone 100 (MDI) 40

Fluticasone 50-500 (MDI & DPI)

0.20, 0.25, Budesonide 100, 200, 400 (DPI) 0.

Beclomethasone 50-400 (MDI & DPI) 0.2-0.

Oral

Solution Drug Inhaler for

Glucocorticosteroids

{ long-term inhaled steroids reduce mortality from all causes in patients with COPD

Thorax 2005;60:992–

20

Tiotropium

{ Tiotropium, a long-acting anticholinergic agent,reduces frequency of exacerbations & use of health care resources in patients with moderate to severe COPD

Ann Intern Med 2005;143:317–

Theophylline

{ Oral theophylline only if inhaled treatments have failed to provide adequate relief

{ All studies that have shown efficacy of theophylline in COPD were done with slow-release preparations

{ Addition of theophylline to ß2-agonists or anticholinergics may produce additional improvements in lung function and health status

{ Combination of salbutamol with theophylline in a single tablet not recommended